The inductive treatment of erlotinib before operation in patients with NSCLC in stage ⅢA
- VernacularTitle:厄洛替尼在ⅢA期肺癌术前诱导治疗中的应用
- Author:
Gaofeng LI
;
Qian WANG
;
Yongxin JIANG
;
Weiwei WANG
;
Nan CHEN
- Publication Type:Journal Article
- Keywords:
Carcinoma,Non-small-cell lung;
Erlotinib;
Stage ⅢA
- From:
Cancer Research and Clinic
2008;20(8):532-533
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of erlotinib in patients with non-small-cell lung cancer (NSCLC)in stage ⅢA before operation and the relation with the rate of resection,good operability and postoperative complications.Methods 31 patients with NSCLC in stage ⅢA in group A were treated with erlotinib before operation;34 patients with NSCLC in stage ⅢA in group B only were treated with operation.Results The condition of 64.5%patients were improved.The operability in group A was more than that in group B(P=0.008),the good operability in group A was more than that in group B(P=0.011),the postoperative complications do not have statistical significance (P=0.07).Conclusion The erlotinib can increase the rate of resection in patients with NSCLC in stage ⅢA,and increase good operability in patients with NSCLC in stage ⅢA,but not increase the postoperative complications.
